Conference Coverage
Conference Coverage
Ixekizumab has profound impact on genital psoriasis
GENEVA – A swift improvement in the “incredibly debilitating” disease was observed in the randomized trial.
Conference Coverage
Unresolved fatigue lingers for most PsA patients
MADRID – Three factors appear most responsible for the majority of reported patient fatigue.
Conference Coverage
Children with psoriasis face multitude of comorbidities
CHICAGO – Obesity ranks as the most well-understood comorbidity of psoriasis in children. Furthermore, many obese children with psoriasis may also...
Conference Coverage
Ixekizumab helps PsA patients who failed a TNFi
MADRID – Ixekizumab appears to be a good second-line choice for TNFi-unresponsive patients.
Conference Coverage
Comorbidities in psoriatic arthritis flag worse prognosis
MADRID - Focus on comorbidities to improve treatment.
Conference Coverage
Early phase III data positive for adalimumab biosimilar, for both psoriasis and PsA
Response curves were nearly identical for adalimumab and the biosimilar
Conference Coverage
Apremilast eases PsA symptoms in patients who are naive to biologics
MADRID - Response to the drug increased over time.
Conference Coverage
Panel revises spondyloarthritis treat-to-target recommendations
MADRID – Nearly half of the recommendations now backed by evidence.
Conference Coverage
Ustekinumab trumps TNF-blockade for enthesitis in patients with psoriatic arthritis
After 6 months, 71% of those taking ustekinumab showed total enthesitis clearance.
Conference Coverage
VIDEO: Guselkumab bests placebo in psoriatic arthritis
MADRID – The IL-23 blocker bested placebo on ACR 20 response and each secondary endpoint.